Literature DB >> 18431096

Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.

Reema H Syed1, Terry L Moore.   

Abstract

Methylphenidate and dextroamphetamine are central nervous system stimulants used in the treatment of attention deficit hyperactivity disorders in children. These medications have been associated with cerebral arteritis, renal necrotizing vasculitis, and systemic and pulmonary hypertension. We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon. Two patients were found to have a positive ANA at low titers, 1 of whom had histopathologic evidence of stratum malgiphian necrosis with perivascular lymphocytic infiltration on skin biopsy. Two had positive antihistone antibodies. One patient improved after withdrawal of dextroamphetamine; others had worsening of their symptoms on higher doses of medications. These cases indicate the potential for development of acral cyanosis, livedo reticularis, or Raynaud symptoms with these medications and their potential contribution to a vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431096     DOI: 10.1097/RHU.0b013e3181639aaa

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  8 in total

1.  Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats.

Authors:  Felipe Schmitz; Emilene Barros da Silva Scherer; Maira Jaqueline da Cunha; Aline Andrea da Cunha; Daniela Delwing Lima; Débora Delwing; Carlos Alexandre Netto; Angela Terezinha de Souza Wyse
Journal:  Mol Cell Biochem       Date:  2011-10-20       Impact factor: 3.396

Review 2.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 3.  ADHD in children and youth: Part 2-Treatment.

Authors:  Mark E Feldman; Alice Charach; Stacey A Bélanger
Journal:  Paediatr Child Health       Date:  2018-10-24       Impact factor: 2.253

4.  Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center.

Authors:  Zahra Khajehpiri; Javad Mahmoudi-Gharaei; Toktam Faghihi; Iman Karimzadeh; Hossein Khalili; Mostafa Mohammadi
Journal:  J Res Pharm Pract       Date:  2014-10

5.  Secukinumab-induced Raynaud's phenomenon: first report in the literature.

Authors:  Senol Kobak
Journal:  Ther Adv Drug Saf       Date:  2020-02-22

6.  Blood Pressure, Heart Rate, and CNS Stimulant Medication Use in Children with and without ADHD: Analysis of NHANES Data.

Authors:  Susan M Hailpern; Brent M Egan; Kimberly D Lewis; Carol Wagner; Ghassan F Shattat; Doaa I Al Qaoud; Ibrahim F Shatat
Journal:  Front Pediatr       Date:  2014-09-19       Impact factor: 3.418

7.  Risperidone Related Raynaud's Phenomenon: An Adolescent Case.

Authors:  Serkan Güneş; Özalp Ekinci; Halenur Teke; Veli Yıldırım
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-02-28       Impact factor: 2.582

8.  Chilblains in children in the setting of COVID-19 pandemic.

Authors:  David Andina; Lucero Noguera-Morel; Marta Bascuas-Arribas; Jara Gaitero-Tristán; José Antonio Alonso-Cadenas; Silvia Escalada-Pellitero; Ángela Hernández-Martín; Mercedes de la Torre-Espi; Isabel Colmenero; Antonio Torrelo
Journal:  Pediatr Dermatol       Date:  2020-05-22       Impact factor: 1.997

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.